Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic786 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,965 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (538)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05256277 | NK Cell Therapy for AML | terminated | Phase 1 | 3 | Zhejiang UniversityOTHER | 1 | May 16, 2023 | clinicaltrials |
| NCT05330377 | GM-CLAG in Relapsed/Refractory FLT3-mutated AML | withdrawn | Phase 1 | 0 | Ayman H QasrawiOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT02891278 |
| completed |
| Phase 1 |
| 6 |
| Columbia UniversityOTHER |
| 1 |
| Apr 12, 2023 |
| clinicaltrials |
| NCT03465540 | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | terminated | Phase 1 | 24 | AmgenINDUSTRY | 6 | Apr 12, 2023 | clinicaltrials |
| NCT05697510 | Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM(SILTUXILAM) | unknown | Phase 1 | 12 | Nantes University HospitalOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05503355 | A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML | unknown | Phase 1 / Phase 2 | 80 | BioSight Ltd.INDUSTRY | 1 | Apr 4, 2023 | clinicaltrials |
| NCT02878785 | Decitabine and Talazoparib in Untreated AML and R/R AML(1565GCC) | completed | Phase 1 / Phase 2 | 25 | University of Maryland, BaltimoreOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05448599 | A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS | unknown | Phase 1 / Phase 2 | 120 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Mar 15, 2023 | clinicaltrials |
| NCT03878927 | CPX-351+GO in Subjects 55 Years Old, or Older, With AML(CPX GO) | terminated | Phase 1 | 11 | Weill Medical College of Cornell UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05513612 | Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies | withdrawn | Phase 1 | 0 | Shanghai Pudong HospitalOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT03303339 | Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 72 | Cardiff OncologyINDUSTRY | 1 | Feb 27, 2023 | clinicaltrials |
| NCT05740917 | To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS | unknown | Phase 1 | 82 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 23, 2023 | clinicaltrials |
| NCT02056782 | A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia(PGX-AML) | completed | Phase 1 | 12 | Jazz PharmaceuticalsINDUSTRY | 0 | Feb 21, 2023 | clinicaltrials |
| NCT02890758 | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | completed | Phase 1 | 14 | Brenda Cooper, MDOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04669067 | TL-895 and KRT-232 Study in Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 18 | Telios Pharma, Inc.INDUSTRY | 8 | Feb 17, 2023 | clinicaltrials |
| NCT02960646 | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT03194932 | Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage | completed | Phase 1 | 62 | St. Jude Children's Research HospitalOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05223699 | Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB) | terminated | Phase 1 | 22 | Magenta Therapeutics, Inc.INDUSTRY | 1 | Feb 9, 2023 | clinicaltrials |
| NCT02323113 | Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 43 | Calithera Biosciences, IncINDUSTRY | 2 | Feb 8, 2023 | clinicaltrials |
| NCT02743351 | Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 96 | Fate TherapeuticsINDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05665075 | Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia | unknown | Phase 1 | 19 | Zhejiang UniversityOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT05665114 | Natural Killer(NK) Cell Therapy in r/r AML | unknown | Phase 1 | 18 | Zhejiang UniversityOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT02996474 | Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 10 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 28, 2022 | clinicaltrials |
| NCT03393611 | CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 14 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT04402723 | Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML | terminated | Phase 1 | 8 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT04543305 | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 | 16 | Prelude TherapeuticsINDUSTRY | 1 | Nov 15, 2022 | clinicaltrials |
| NCT03214666 | GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | terminated | Phase 1 / Phase 2 | 12 | GT Biopharma, Inc.INDUSTRY | 1 | Nov 10, 2022 | clinicaltrials |
| NCT04038437 | A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML | completed | Phase 1 | 35 | Jazz PharmaceuticalsINDUSTRY | 1 | Nov 9, 2022 | clinicaltrials |
| NCT03855371 | Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS(PANDA-T0) | unknown | Phase 1 | 5 | Ruijin HospitalOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT04022785 | PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT05246384 | Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Rhizen Pharmaceuticals SAINDUSTRY | 0 | Oct 31, 2022 | clinicaltrials |
| NCT05497310 | Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL | unknown | Phase 1 / Phase 2 | 15 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT01586455 | Human Placental-Derived Stem Cell Transplantation(HPDSC) | completed | Phase 1 | 43 | New York Medical CollegeOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT01842672 | Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia(MITCL) | completed | Phase 1 / Phase 2 | 41 | New York Medical CollegeOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT05587088 | Evaluation of the Safety and Efficacy of Esperanza Extract (PA001)(PA001) | unknown | Phase 1 / Phase 2 | 82 | Hospital Universitario San IgnacioOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT05584761 | Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML | recruiting | Phase 1 / Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT05577611 | An Open, Single Center, Randomized Controlled Clinical Study of UCB (Cord Blood) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | unknown | Phase 1 | 57 | Zhongnan HospitalOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT03825367 | Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML | unknown | Phase 1 / Phase 2 | 13 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT01373515 | Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 12 | MendusINDUSTRY | 1 | Oct 10, 2022 | clinicaltrials |
| NCT04496999 | HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.(HDMM) | terminated | Phase 1 | 2 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT02403310 | A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML | completed | Phase 1 | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT03516760 | Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia | terminated | Phase 1 | 36 | AvenCell Europe GmbHINDUSTRY | 1 | Sep 29, 2022 | clinicaltrials |
| NCT03218683 | Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies. | terminated | Phase 1 | 70 | AstraZenecaINDUSTRY | 1 | Sep 23, 2022 | clinicaltrials |
| NCT01555268 | Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia | completed | Phase 1 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT03455140 | A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)(PARC) | completed | Phase 1 / Phase 2 | 49 | University of BirminghamOTHER | 3 | Sep 2, 2022 | clinicaltrials |
| NCT02287233 | A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 94 | AbbVieINDUSTRY | 4 | Aug 29, 2022 | clinicaltrials |
| NCT02582359 | MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age | completed | Phase 1 | 39 | Massachusetts General HospitalOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT02267863 | A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS | terminated | Phase 1 | 21 | Aptose Biosciences Inc.INDUSTRY | 1 | Aug 22, 2022 | clinicaltrials |
Data updated 24 days agoSource updated May 16, 2023source: clinicaltrials